Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CapsoVision, Inc

NASDAQ: CV · Industrial Applications and Services · 6 alerts · CIK 1378325

Share price
$6.47Close, Nov 16
Market cap
$347M
Shares outstanding
53.61MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CapsoVision, Inc filings on SEC EDGAR ↗

4:40 PM ET 10-Q
Financial Results

CapsoVision Q3 2026 Results: Net Loss of $7.34M, Loss Narrows

CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.

Key figure
Net loss $7.34M
4:35 PM ET 8-K
Financial Results

CapsoVision Financial Results

CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.

Term
Q3 2026

“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”

Johnny Wang, President and Chief Executive Officer

“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”

Johnny Wang, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.